Drug Profile
Gremubamab - AstraZeneca
Alternative Names: Anti-Psl/PcrV; MEDI-3902Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Antibacterials; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Bacterial polysaccharide inhibitors; PcrV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Nosocomial pneumonia
Most Recent Events
- 09 Dec 2020 Safety, efficacy and pharmacokinetics data from the phase II EVADE trial in Nosocomial pneumonia presented at the IDWeek 2020 (IDW-2020)
- 29 Apr 2020 Discontinued - Phase-II for Nosocomial pneumonia (In the elderly, Prevention, In adults) in Slovakia, Germany, United Kingdom, Turkey, Spain, Portugal, Israel, Ireland, Hungary, Greece, Czech Republic, Croatia, Belgium, Austria, USA, France (IV), due to safety/efficacy reasons (AstraZeneca pipeline, April 2020)
- 19 Jul 2018 Phase II development is ongoing for Nosocomial pneumonia in USA (NCT02696902)